GOTHENBURG, SWEDEN / ACCESSWIRE / February 28, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, February 28, 2024 – IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company will present at the scientific conference Bayes@Lund 2024 on March 7, 2024.
The accepted abstract on use of Bayesian model in clinical trial planning and execution is titled “Using a Bayesian model for clinical study design and blinded data review.” The abstract has been accepted as an oral presentation that will be held by IRLAB:s co-worker Erik Werner, PhD, on March 7, and will be made available on YouTube after the completion of the conference.
For more details about the Bayes@Lund 2024 congress, please visit https://www.bayesatlund.com
For more information:
Gunnar Olsson, CEO
Phone: +46 70 576 14 02
E-mail: gunnar.olsson@irlab.se
About IRLAB
IRLAB is discovering and developing a portfolio of transformative therapies targeting all stages of Parkinson’s disease. The company has its origin in Nobel Laureate Prof. Arvid Carlsson’s research group and the discovery of a connection between the brain’s neurotransmitters and CNS disorders. Mesdopetam (IRL790), in development for the treatment of levodopa-induced dyskinesias, has completed Phase IIb and is in preparation toward Phase III. Pirepemat (IRL752), is currently in Phase IIb, being evaluated for its effect on balance and fall frequency in Parkinson’s disease. In addition, the company is also progressing the three preclinical programs IRL757 (financially supported by the Michael J. Fox Foundation), IRL942, and IRL1117 towards Phase I studies. IRLAB’s pipeline has been generated by the company’s proprietary systems biology-based Integrative Screening Process (ISP) research platform. Headquartered in Sweden, IRLAB is listed on Nasdaq Stockholm (IRLAB A). For more information, please visit www.irlab.se.
Attachments
IRLAB to present at the Bayes@Lund 2024 Conference in Lund, Sweden on March 7
SOURCE: IRLAB Therapeutics
View the original press release on accesswire.com
GALWAY, Ireland, June 11, 2025 /PRNewswire/ -- TE Connectivity plc (NYSE: TEL) announced today that…
BROOKFIELD, Wis., June 11, 2025 /PRNewswire/ -- SRM Equity Partners ("SRM"), an operationally focused private…
MSD Solutions Lab programs unite academic researchers and industry partners to drive innovation WASHINGTON, June…
Darby 3.0 automates patient intake workflows from fax to EMR, helping HME providers scale without…
Empowering researchers at every level to test hypotheses, validate findings, and collaborate to advance science…
— One of 65 startups chosen from nearly 1,500 global applicants — — Selected to…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
